Juno Therapeutics Inc (JUNO) Short Interest Update

Juno Therapeutics Inc (NASDAQ:JUNO) was the recipient of a large drop in short interest in January. As of January 31st, there was short interest totalling 3,637,584 shares, a drop of 58.8% from the January 12th total of 8,834,492 shares. Currently, 4.3% of the company’s stock are sold short. Based on an average daily volume of 10,485,500 shares, the days-to-cover ratio is currently 0.3 days.

In other Juno Therapeutics news, EVP Robert Azelby sold 1,816 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares in the company, valued at approximately $3,184,606.72. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard Klausner sold 36,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $44.76, for a total value of $1,611,360.00. Following the sale, the director now owns 744,392 shares of the company’s stock, valued at approximately $33,318,985.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 468,874 shares of company stock valued at $26,675,574. 15.08% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisor Group Inc. lifted its holdings in shares of Juno Therapeutics by 141.1% in the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares during the last quarter. Comerica Bank bought a new stake in shares of Juno Therapeutics in the 4th quarter worth approximately $240,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares during the last quarter. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 3,559 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in shares of Juno Therapeutics in the 4th quarter worth approximately $173,000. 69.13% of the stock is currently owned by institutional investors and hedge funds.

JUNO has been the subject of a number of recent analyst reports. SunTrust Banks upgraded Juno Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 2nd. Cowen restated a “buy” rating and set a $49.00 price objective on shares of Juno Therapeutics in a research note on Friday, October 27th. Raymond James Financial raised their price objective on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Wedbush reaffirmed an “outperform” rating and set a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a report on Thursday, November 2nd. Finally, Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $51.20.

Shares of Juno Therapeutics (JUNO) opened at $85.69 on Friday. The stock has a market capitalization of $9,780.00, a P/E ratio of -25.28 and a beta of 3.42. Juno Therapeutics has a 1-year low of $19.62 and a 1-year high of $86.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) EPS. analysts forecast that Juno Therapeutics will post -4.02 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Juno Therapeutics Inc (JUNO) Short Interest Update” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/10/juno-therapeutics-inc-juno-short-interest-update.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply